

Azathioprine

Azathioprine is a conventional immunomodulatory drug that is rarely used to treat AE nowadays due to the availability of more advanced therapeutic options. However, in cases where there are contraindications or limitations to other recommended systemic treatments, azathioprine may still be considered as a treatment option on an individual basis.

Mechanisms of action and efficacy

AZA is a pro-drug which is rapidly converted in vivo to the anti-metabolite 6-mercaptopurine (6-MP), following cleavage of its imidazole side chain. It is believed to exert its primary immunosuppressant effect via metabolites of 6-MP, thioguanine nucleotides (TGNs), which are subsequently incorporated into DNA, inhibiting its synthesis.¹

The efficacy of AZA is comparable to that of MTX but lower compared to dupilumab or cyclosporine A in clearing clinical signs of AE.²

Randomized clinical trials report a significant superiority of AZA vs placebo, with a decrease in clinical scores such as Six Area, Six Sign Atopic Dermatitis and Scoring Atopic Dermatitis (SASSAD) by 26% to 39% after 12 weeks.³ However, results from retrospective studies are less favorable with a percentage of AZA treatment failure varying from 30 to 57% due to adverse effects or lack of effectiveness.⁴⁻⁶ An observational follow-up study of 36 adult patients with severe AE treated with MTX or AZA over a 24-week period demonstrated less improvement in subjects with filaggrin mutations (36%, 13/36) compared to those without filaggrin mutations.³

Long-term studies on adult patients treated with either AZA or MTX showed a relative reduction in SCORAD of 53% ($P < .01$) and 63% ($P < .01$) after 2 years, and 54% and 53% after 5 years, respectively.^{3, 7} Patients with a Filaggrin mutation seemed to have slower but prolonged effects of therapy compared with patients without a mutation.^{3, 7}

Dosage: acute flare, short term, long term

- off licence
- commonly used dosage
 - adults and children: 1-3 mg/kg bodyweight per day
 - If no improvement of AE occurs within 3 months, withdrawing azathioprine should be considered.
- We recommend combining AZA, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients.
- If timely thiopurine S-methyltransferase (TPMT) activity measurement is available, the following dosing of AZA has been suggested:
 - very low activity (< 2.5 per mL red blood cells [RBC]), treatment should not be started
 - intermediate activity (2.5-7.5 nmol/h/mL RBC): 0.5 mg/kg bodyweight per day for the first 4 weeks and then increase to 1.0 mg/kg bodyweight per day
 - normal activity (>7.5 nmol/h/mL RBC): 2.0 mg/kg bodyweight per day for the first 4 weeks and then increase to 2.5-3.0 mg/kg bodyweight per day

Low azathioprine doses (0.5-1.0 mg/kg bodyweight per day) for the first 4 weeks were shown to reduce gastrointestinal side-effects.⁸

If TPMT results are not available prior to starting AZA therapy, then half of the standard treatment dose should be given for about 4-6 weeks under close monitoring of full blood count and liver profile, prior to going up the full treatment dose.

Safety

In the short and medium term, the most commonly reported serious dose-dependent effects are hepatotoxicity and myelotoxicity, together with gastrointestinal disturbances. Further, idiosyncratic hypersensitivity reactions (e.g. fever, rigors, myalgia, arthralgia and occasionally pancreatitis) may occur.⁹

Concerns have been raised about the potential carcinogenicity induced by long-term treatment with azathioprine (predominantly squamous cell skin cancer and non-Hodgkin's lymphoma), especially if AZA is combined with other immunosuppressant regimens.¹⁰

Screening and monitoring

- Baseline screening:
 - Complete blood count, renal and liver profile
 - TPMT activity if available
 - Screening for chronic infections (e.g. hepatitis B-/C, HIV) before therapy should be considered (see also section 8.1 Introduction conventional immunomodulatory drugs)
- Follow up monitoring: Complete blood count, renal and liver profile twice monthly for 2 months, monthly for 4 months, then every 2-3 months and with dose increases. Please note that local hospital may have other guidance in place, and the frequency of such and other investigations needs to be adjusted to individual patient needs.
- Pregnancy testing before and during AZA therapy where indicated

Combination with other treatments

We recommend combining azathioprine, as any systemic treatment, with emollients and, whenever needed, topical anti-inflammatory treatment in AE patients. Because of a potentially increased risk to develop skin cancer, AZA should not be combined with UV light therapy (UVA, UVB, PUVA).

Special considerations

There is a theoretical risk of teratogenesis with AZA. This is based on studies in animals in which very high doses of AZA were used. However, in practice AZA has been used for over 30 years in sexually active men and women and no definite association between the drug and the incidence of fetal abnormalities has been observed. There also seems to be no effect on fertility.

According to a position paper by ETFAD¹¹, AZA use during pregnancy should be avoided as there are better options, but AZA may be used off-label in the absence of other alternatives as continuation of treatment in women already receiving this treatment at the time of conception. According to experts' opinion of the ETFAD, the dosage of azathioprine should be reduced by 50% if it is continued during pregnancy. Initiation of azathioprine after conception should be avoided.

The use of AZA during lactation is debated. The WHO has recommended that the potential side-effects of AZA outweigh the effects and benefits of the treatment¹², and studies suggest that AZA intake during

breastfeeding could increase the long-term risk of immunosuppression and carcinogenesis in the child.¹³

AZA is not licensed for the treatment of AE in children but it has proven beneficial in several retrospective pediatric case series. The main disadvantage of AZA is that it reaches its maximum treatment effect only after 3-4 months.¹⁴

References

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. *Eur J Clin Pharmacol* 1992;43(4):329–39.
2. Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochweg B et al. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. *JAMA Dermatol* 2020;156(6):659–67.
3. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. *J Allergy Clin Immunol* 2014;133(2):429–38.
4. Thomsen SF, Karlsmark T, Clemmensen KK, Graversgaard C, Ibler KS, Jemec GB et al. Outcome of treatment with azathioprine in severe atopic dermatitis: a 5-year retrospective study of adult outpatients. *Br J Dermatol* 2015;172(4):1122–4.
5. Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres. *J Eur Acad Dermatol Venereol* 2015;29(10):1905–12.
6. van der Schaft J, van Zuilen AD, Deinum J, Buijnzeel-Koomen CA, de Bruin-Weller MS. Serum creatinine levels during and after long-term treatment with cyclosporine A in patients with severe atopic dermatitis. *Acta Derm Venereol* 2015;95(8):963–7.
7. Gerbens LAA, Hamann SAS, Brouwer MWD, Roekevisch E, Leeflang MMG, Spuls PI. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. *Br J Dermatol* 2018;178(6):1288–96.
8. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. *Lancet* 2006;367(9513):839–46.
9. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. *Clin Exp Dermatol* 2001;26(5):369–75.
10. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. *Acta Derm Venereol* 1992;72(2):115–9.
11. Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. *J Eur Acad Dermatol Venereol* 2019;33(9):1644–59.
12. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. *Br J Dermatol* 2011;165(4):711–34.
13. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. *Arch Intern Med* 2000;160(5):610–9.
14. Noguera-Morel L, Knöpfel N, Torreló A, Hernández-Martín A. A Retrospective Study of Systemic Treatment of Severe Atopic Dermatitis With Azathioprine: Effectiveness and Tolerance in 11 Pediatric Patients. *Actas Dermosifiliogr* 2019;110(3):227–31. Estudio retrospectivo del tratamiento sistémico de la dermatitis atópica grave con azatioprina. Eficacia y tolerancia en 11 pacientes pediátricos.